BRCA2 and ovarian serous cystadenocarcinoma: BRCA1 and BRCA2 mutations, previouslyidentified in both sporadic and hereditary serous ovarian cancer,6, 54 had significant decreases in the TCGA Ovarian Serous Cystadenocarcinoma dataset, BRCA1 (F = 3.81; Pr(>F) = 0.023) and BRCA2 (F = 12.8; Pr(>F) = 3.95 x 10−6), Figure 3F‐G.